Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a pivotal class of medications primarily used in the treatment of type 2 diabetes mellitus (T2DM) and obesity [1, 2]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.